SynAct Pharma – The sharp take: insights from the capital markets day

Immune suppression has long been the default in treating inflammation, delivering symptom relief but often at the cost of safety, durability and true disease modification. SynAct Pharma is challenging this paradigm with a next wave approach built on pro resolution biology, designed to switch off inflammation by restoring immune balance rather than shutting it down. By reprogramming macrophages towards a pro resolving state, SynAct aims to move treatment beyond symptom control towards meaningful disease modification. At the centre of this strategy is its lead asset, resomelagon (AP1189), a melanocortin receptor agonist designed to drive this pro resolving response.

The video takes viewers behind the scenes of SynAct’s capital markets day, translating complex science into sharp, bite-sized, investor relevant takeaways. Management and experts highlight the structural limitations of current standards of care (eg NSAIDs, steroids, JAK inhibitors), reinforcing the need for safer, more targeted solutions that can be deployed earlier in the disease pathway. SynAct’s dual pronged strategy spans chronic conditions such as rheumatoid arthritis and acute inflammatory settings including viral and respiratory infections (such as dengue, influenza, RSV and COVID-19), where controlling hyperinflammation is critical.

With multiple near term data catalysts (including topline Phase IIa data in rheumatoid arthritis in mid-2026) and active partnering discussions, SynAct is building momentum as it transitions into a pivotal, execution led phase.